
    
      This is a multicenter, single-arm, Phase 2 trial to assess the efficacy and safety of
      single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or
      metastatic human epidermal growth factor receptor (HER2)-negative breast cancer. A total of
      52 adult female subjects will be enrolled and treated with eribulin mesylate (1.4 mg/m2 as an
      intravenous [i.v.] infusion over 2 to 5 minutes on Days 1 and 8 of each 3-week cycle).
    
  